{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:29:07Z","timestamp":1760149747339,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK, Japan","award":["208506","NCT03543150"],"award-info":[{"award-number":["208506","NCT03543150"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>This postmarketing surveillance study was conducted to evaluate the safety and effectiveness of onabotulinumtoxinA in Japanese patients with laryngeal dystonia (LD). Patients receiving onabotulinumtoxinA for the first time were enrolled and observed for up to 12 months following the first injection. Safety assessment included adverse drug reactions (ADRs), and effectiveness assessments included the Voice Handicap Index-10 (VHI-10) and physician\u2019s global assessment (PGA). ADRs were observed in 48 (5.8%) of 834 patients in the safety analysis set, including dysphonia in 43 (5.2%) patients and dysphagia in 7 (0.8%) patients. The change in total VHI-10 score (mean) in 790 patients included in the effectiveness analysis set showed that improvement in adductor LD peaked at 2 months after the first injection, while patients with abductor or mixed LD showed a gradual attenuation of effect 2\u20134 weeks post-injection. The change in total VHI-10 score in subsequent injections was generally similar to that following the first injection. The overall effectiveness rate according to the PGA was 93.4% (738\/790 patients). The results demonstrate that onabotulinumtoxinA is a well-tolerated and effective treatment for LD in real-world clinical practice.<\/jats:p>","DOI":"10.3390\/toxins15090553","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T10:26:43Z","timestamp":1693909603000},"page":"553","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Effectiveness of OnabotulinumtoxinA in Patients with Laryngeal Dystonia: Final Report of a 52-Week, Multicenter Postmarketing Surveillance Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Shigeomi","family":"Iimura","sequence":"first","affiliation":[{"name":"VEO Specialty Care, Value Evidence Outcome, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyo","family":"Nose","sequence":"additional","affiliation":[{"name":"VEO Specialty Care, Value Evidence Outcome, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Tabata","sequence":"additional","affiliation":[{"name":"PMS Data Management, Value Evidence Outcome, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-3098","authenticated-orcid":false,"given":"Kenji","family":"Oda","sequence":"additional","affiliation":[{"name":"Real World Data Analytics, Value Evidence Outcome, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Specialty Medical Affairs, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"PMS, Value Evidence Outcome, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"VEO Specialty Care, Value Evidence Outcome, Japan Medical and Development, GlaxoSmithKline K.K., Tokyo 107-0052, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"ref_1","unstructured":"Aronson, A.E., and Bless, D.M. (2009). Clinical Voice Disorders, Thieme. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1288\/00005537-198806000-00012","article-title":"Clinical and laboratory characteristics of focal laryngeal dystonia: A study of 110 cases","volume":"98","author":"Blitzer","year":"1988","journal-title":"Laryngoscope"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1111\/ene.14714","article-title":"Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison\/open-label clinical trial","volume":"28","author":"Hyodo","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/lary.24292","article-title":"Voice disorders in the workplace: Productivity in spasmodic dysphonia and the impact of botulinum toxin","volume":"123","author":"Meyer","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group (2000). A prevalence study of primary dystonia in eight European countries. J. Neurol., 247, 787\u2013792.","DOI":"10.1007\/s004150070094"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.anl.2020.08.013","article-title":"The prevalence and clinical features of spasmodic dysphonia: A review of epidemiological surveys conducted in Japan","volume":"48","author":"Hyodo","year":"2021","journal-title":"Auris Nasus Larynx."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jvoice.2014.09.030","article-title":"The comparison of thyroarytenoid muscle myectomy and type II thyroplasty for spasmodic dysphonia","volume":"29","author":"Nomoto","year":"2015","journal-title":"J. Voice"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0967-5868(03)00020-1","article-title":"Spasmodic dysphonia: Clinical features and effects of botulinum toxin therapy in 169 patients-an Australian experience","volume":"10","author":"Tisch","year":"2003","journal-title":"J. Clin. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-1331.2010.03047.x","article-title":"Spasmodic dysphonia and botulinum toxin: Experience from the largest treatment series","volume":"17","author":"Blitzer","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_10","first-page":"S1","article-title":"Clinical practice guideline: Hoarseness (dysphonia) (update)","volume":"158","author":"Stachler","year":"2018","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","article-title":"Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients","volume":"108","author":"Blitzer","year":"1998","journal-title":"Laryngoscope"},{"key":"ref_12","unstructured":"European Medicines Agency (2023, May 18). Important Medical Event Terms List (MedDRA Version 24.1), Available online: https:\/\/www.alims.gov.rs\/wp-content\/uploads\/2022\/02\/IME_list_version_241.pdf."},{"key":"ref_13","first-page":"237","article-title":"Laryngeal dystonia (spasmodic dysphonia): Observations of 901 patients and treatment with botulinum toxin","volume":"78","author":"Brin","year":"1998","journal-title":"Adv. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/lary.21395","article-title":"Botulinum toxin treatment of adductor spasmodic dysphonia: Longitudinal functional outcomes","volume":"121","author":"Novakovic","year":"2011","journal-title":"Laryngoscope"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/000348940111000503","article-title":"Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia","volume":"110","author":"Bielamowicz","year":"2001","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.otot.2004.02.007","article-title":"Botulinum toxin treatment of spasmodic dysphonia","volume":"15","author":"Sulica","year":"2004","journal-title":"Oper. Tech. Otolayngol. Head Neck Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.otohns.2008.06.013","article-title":"Vocal outcome measures after bilateral posterior cricoarytenoid muscle botulinum toxin injections for abductor spasmodic dysphonia","volume":"139","author":"Klein","year":"2008","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamaoto.2017.1621","article-title":"Minimal important difference in Voice Handicap Index-10","volume":"143","author":"Misono","year":"2017","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rumbach, A., Aiken, P., and Novakovic, D. (2022). Treatment outcome measures for spasmodic dysphonia: A systematic review. J. Voice, online ahead of print.","DOI":"10.1016\/j.jvoice.2021.10.001"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/553\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:46:40Z","timestamp":1760129200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/9\/553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["toxins15090553"],"URL":"https:\/\/doi.org\/10.3390\/toxins15090553","relation":{},"ISSN":["2072-6651"],"issn-type":[{"type":"electronic","value":"2072-6651"}],"subject":[],"published":{"date-parts":[[2023,9,5]]}}}